This episode reframes antiviral therapy as the pharmacology of interruption. Viruses lack cell walls, metabolism, and independent machinery; they succeed by hijacking ours. Effective drugs therefore target steps in replication-entry, uncoating, genome synthesis, assembly, and release-while sparing host function as much as possible. We explore nucleos(t)ide analogues, polymerase and protease inhibitors, entry and fusion blockers, and host-directed strategies, emphasising timing, resistance, and indication-specific precision.

Key takeaways to sharpen judgement:

* No wall to break: why antivirals must target processes, not structures.

* Replication checkpoints: entry, synthesis, assembly, release-where drugs act.

* Timing matters: early intervention vs limited late benefit.

* Resistance logic: rapid mutation and the need for combinations or barriers to escape.

* Clinical framing: disease severity, host immunity, and duration over breadth.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe